AG真人官方

HeartSciences, Inc. (Nasdaq: HSCS/HSCSW) filed an 8-K to update investors on its ongoing Regulation A offering and a note-for-equity exchange.

• The Form 1-A, qualified on 10 Mar 2025, permits sale of up to 4,285,714 Units at $3.50 each (maximum proceeds $15.0 million). Each Unit comprises one share of Series D Preferred Stock and one warrant exercisable at $5.00 for one common share.
• Through 29 Jul 2025, the company has closed on $4.3 million in gross proceeds, issuing 1,241,188 Units.
• Holders have converted 850,981 Series D shares into an equal number of common shares (the 鈥淩eg A Issuance鈥�).
• Separately, the company exchanged $1.105 million principal of a September 2024 unsecured promissory note for 301,111 common shares, reducing the note by that amount (the 鈥淒ebt Exchange鈥�).
• Post-transactions, 2,244,247 common shares are issued and outstanding as of 29 Jul 2025.

No financial statements were included; the filing was limited to disclosure of these capital transactions.

AEye, Inc. (Nasdaq: LIDR) filed Amendment No. 4 to its 424(b)(5) prospectus, expanding its at-the-market (ATM) program with A.G.P./Alliance Global Partners from an aggregate $2.6 million to up to $75 million of common stock. The company has already issued about $23.7 million under prior supplements, leaving roughly $51.3 million available for future sales.

As of 25-Jul-2025, AEye鈥檚 public float is $129.7 million (29.28 M non-affiliate shares at $4.43), lifting it above the $75 million threshold; therefore, the Form S-3 I.B.6 limitations on incremental offerings no longer apply. The filing reiterates that AEye is an emerging growth and smaller reporting company and highlights the usual high-risk investment language.

The amendment increases capital-raising flexibility, potentially improving liquidity but also introducing dilution risk for existing shareholders as additional shares may be issued at market prices.

Form 4 discloses that AEye (LIDR) director Luis Dussan sold a total of 6,000 Class A common shares on 24 Jul 2025 at an average price of $4.00 per share. The shares were disposed through two family trusts鈥�Luis Dussan Trust A and Jennifer Dussan Trust A鈥攗nder a Rule 10b5-1 trading plan adopted 13 Jun 2024.

After the transactions, Dussan鈥檚 beneficial ownership comprises 238,832 shares (Luis Dussan Trust A), 30,000 shares (Jennifer Dussan Trust A), 12,402 shares (Family Trust), and a direct holding of 3,493 shares, totaling 284,727 shares. The sale represents roughly 2 % of his reported holdings. No derivative securities were traded or reported.

Franklin Financial Services (FRAF) 鈥� Insider transaction summary

EVP/CFO Mark R. Hollar filed a Form 4 for transactions on 07/25/2025:

• Option exercise (Code M): 3,000 common shares acquired at a strike price of $30.00.
• Share withholding (Code F): 2,102 shares surrendered at the market price of $42.83 to fund the cashless exercise.

After the two entries, Hollar鈥檚 direct beneficial ownership stands at 15,572 shares (plus 96 DRIP shares and previously reported unvested RSUs). The net result is an increase of 鈮�898 shares, signalling a modest rise in insider exposure. No derivative securities remain from the 2017 option grant; 2,927 options from a 2018 grant are still outstanding.

Insider option exercises when the market price materially exceeds the strike (鈻� 43%) can indicate executive confidence and are generally viewed positively, although the partial share disposition tempers the signal. The transaction does not impact earnings or guidance but may be of interest to investors tracking insider sentiment.

On 24 Jul 2025 AEye, Inc. (Nasdaq: LIDR) filed Amendment No. 3 to its 424(b)(5) prospectus supplements for its Form S-3 at-the-market (ATM) equity program with A.G.P./Alliance Global Partners. The amendment raises the maximum aggregate offering price that may be sold under the Sales Agreement from $2.6 million to $23.728 million, equal to one-third of the company鈥檚 $71.2 million public float, as permitted by General Instruction I.B.6.

AEye has already issued $14.993 million of securities under this rule in the last 12-month period; combined future sales cannot surpass the updated $23.728 million cap unless a further supplement is filed. Key metrics disclosed: 25.42 million shares outstanding, of which 24.38 million are held by non-affiliates; last reported share price $2.92. The company continues to qualify as an 鈥渆merging growth鈥� and 鈥渟maller reporting鈥� company, benefiting from reduced reporting requirements. Investors are directed to previously disclosed risk factors for additional considerations.

MarineMax (HZO) reported a sharp swing to loss for Q3 FY25. Revenue fell 13% YoY to $657.2 million as new-boat demand softened; nine-month sales declined 6% to $1.76 billion. Gross margin contracted 80 bp to 30.4%, only partly offset by a 5% reduction in SG&A.

A $69.1 million goodwill impairment in the Product Manufacturing unit drove an operating loss of $41.5 million and a net loss of $52.1 million (-$2.42 diluted EPS) versus $31.6 million profit ($1.37 EPS) a year ago. Interest expense remained elevated at $16.9 million.

Cash & equivalents dropped to $151.0 million (-33% YTD) after $27.5 million of buybacks and $51.1 million of contingent-consideration payouts. Floor-plan borrowings rose 4% to $735.2 million, while inventories were flat at $906.2 million. Total liquidity (cash + $100 million revolver) is adequate, and operating cash flow turned positive at $11.4 million versus -$24.9 million last year.

Balance-sheet leverage remains moderate: net debt/EBITDA (LTM, excl. impairment) near 2.4脳. Contingent consideration liabilities were cut to $4.5 million from $81.3 million, easing future cash calls. The company remains a large Sea Ray, Boston Whaler and Azimut dealer, but management flags macro pressure (rates, tariffs) on luxury-boat demand.

Key metrics

• Q3 gross profit: $199.6 m (-18%)
• Q3 SG&A: $172.1 m (-5%)
• YTD operating cash flow: +$11.4 m
• Shares outstanding 21.46 m (7% bought back YoY)